Juan C. Jaen is SVP & Drug Discovery & CSO at ChemoCentryx, Inc. (CCXI). They have made 11 open-market trades across 1 company since 2012, most recently 2026-07-10.
CIK 0001422996
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
5 open-market purchases totalling $1.6M since 2018, against 6 sales. Across 5 scored buys the stock is down 1.6% at ninety days, and 2.1 points behind the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| RCUS | 822,240 | $18.2M |
| CCXI | 30,000 | $319K |
| Total | $18.5M |
Shares reported on the most recent Form 4, priced at the 2026-07-13 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 80% | 60% | 40% |
| Avg Move | +2.4% | +3.5% | -1.6% |
| Alpha | +1.9% | +2.9% | -2.1% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RCUS | SELL · 10b5-1 | 2026-07-09 | 2026-07-13 | $29.63 | $2.0M | +6.0% | +3.1% | -13.3% |
| RCUS | SELL · 10b5-1 | 2026-06-22 | 2026-06-24 | $27.92 | $878K | +5.7% | -0.8% | -6.1% |
| RCUS | SELL | 2026-01-05 | 2026-01-07 | $21.41 | $681K | -0.9% | -5.0% | -0.4% |
| RCUS | SELL | 2025-12-16 | 2025-12-18 | $22.06 | $688K | +8.4% | -0.1% | +1.0% |
| RCUS | SELL · 10b5-1 | 2025-12-04 | 2025-12-05 | $24.71 | $4.1M | -13.4% | -15.4% | -13.6% |
| RCUS | SELL · 10b5-1 | 2025-11-17 | 2025-11-19 | $20.26 | $2.0M | +23.0% | +6.3% | -6.9% |
| RCUS | SELL · 10b5-1 | 2025-10-30 | 2025-11-03 | $20.32 | $175K | +0.5% | +30.1% | +9.9% |
| RCUS | SELL · 10b5-1 | 2025-10-28 | 2025-10-30 | $20.75 | $4.0M | +9.4% | +40.8% | +17.0% |
| RCUS | SELL · 10b5-1 | 2024-02-26 | 2024-02-28 | $20.10 | $1.0M | -2.8% | -5.5% | -19.8% |
| RCUS | SELL · 10b5-1 | 2024-01-02 | 2024-01-04 | $20.09 | $280K | -8.7% | -18.2% | -4.9% |
| RCUS | SELL | 2022-12-16 | 2022-12-16 | $30.71 | $251K | -33.9% | -33.7% | -44.7% |
| RCUS | SELL | 2022-06-16 | 2022-06-21 | $21.45 | $104K | +16.7% | +26.1% | +12.5% |
| RCUS | SELL | 2021-12-16 | 2021-12-20 | $40.12 | $79K | -1.3% | -18.3% | -15.6% |
| RCUS | SELL | 2021-06-16 | 2021-06-21 | $23.96 | $167K | +19.0% | +37.1% | +51.7% |
| RCUS | BUY | 2019-06-27 | 2019-06-28 | $7.53 | $189K | +4.3% | -1.5% | +7.8% |
| RCUS | BUY | 2019-06-03 | 2019-06-04 | $8.25 | $83K | +2.6% | +7.8% | -8.8% |
| RCUS | BUY | 2018-11-13 | 2018-11-15 | $11.80 | $118K | +0.3% | +3.0% | -2.8% |
| RCUS | BUY | 2018-08-09 | 2018-08-13 | $11.90 | $170K | +12.8% | +10.3% | +0.4% |
| RCUS | BUY | 2018-03-19 | 2018-03-19 | $15.00 | $1000K | -7.9% | -2.1% | -4.5% |
| CCXI | SELL · 10b5-1 | 2013-03-07 | 2013-03-11 | $13.97 | $39K | -48.7% | -9.1% | -9.1% |
| CCXI | SELL · 10b5-1 | 2013-03-04 | 2013-03-06 | $13.97 | $170K | -48.7% | -9.1% | -9.1% |
| CCXI | SELL · 10b5-1 | 2013-02-27 | 2013-03-01 | $12.79 | $161K | -48.7% | -9.1% | -9.1% |
| CCXI | SELL · 10b5-1 | 2013-02-22 | 2013-02-26 | $12.23 | $275K | -48.7% | -9.1% | -9.1% |
| CCXI | SELL · 10b5-1 | 2013-02-19 | 2013-02-21 | $11.90 | $264K | -48.7% | -9.1% | -9.1% |
| CCXI | SELL · 10b5-1 | 2013-02-15 | 2013-02-19 | $11.74 | $23K | -48.7% | -9.1% | -9.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.